81% of Clinical Trial Volunteers Suffer Reactions to CanSino Biologics’ COVID-19 Vaccine

Just under 10% experienced grade 3 reactions. The U.S. Department of Health and Human Services (HHS) describes a Grade 3 adverse event as “severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care” such as “bathing, dressing and undressing, feeding self, using the toilet, taking medications.”

Nwo Report

Source:Joe Martino

IN BRIEF

  • The Facts:Multiple clinical trials for COVID-19 vaccines have shown severe reactions within 10 days after taking the vaccine.
  • Reflect On:Should we think twice about taking a rushed vaccine? Is it even necessary given the remarkably low death rate?

What Happened:COVID-19 vaccines have been in production for several months now, and clinical trials have been underway in various countries. Oneexperimental vaccine being developed by CanSino Biologics, Inc. of Tianjin, China, hascompleted phase1 of human clinical trials for COVID-19 vaccine (adenovirus type-5 Ad5-nCoV) and involved 108 volunteers, ranging in age from 45–60 years old.advertisement -learn more

Participants were given various levels of dosing, from low to high. 87 (or 81%) of the 108 participants experienced at least one adverse reaction within seven days after receiving the vaccination. Of the 87 who had reactions, 30 were in the low dose group, 30 were in…

View original post 313 more words

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.